Home1CG • FRA
Crispr Therapeutics AG
€37.40
2.09%
-0.80 Today
Jun 11, 10:15:00 PM UTC+2 · EUR · FRA · Disclaimer
In the news
Financials
Income Statement
-100M-50M0
Revenue
Net Income
Revenue
Net income
(USD)Mar 2025Y/Y change
Revenue
865.00K71.63%
Operating expense
19.30M7.48%
Net income
-136.00M-16.64%
Net profit margin
-15.72K32.04%
Earnings per share
-1.58-10.49%
EBITDA
-143.69M-5.84%
Effective tax rate
-0.82%
01B2B
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD)Mar 2025Y/Y change
Cash and short-term investments
1.86B-11.99%
Total assets
2.17B-11.19%
Total liabilities
336.94M-5.11%
Total equity
1.83B
Shares outstanding
86.36M
Price to book
1.80
Return on assets
-16.84%
Return on capital
-17.65%
-200M0200M
Net Change in Cash
Net change in cash
(USD)Mar 2025Y/Y change
Net income
-136.00M-16.64%
Cash from operations
-53.95M-149.15%
Cash from investing
-19.76M79.80%
Cash from financing
10.59M-96.54%
Net change in cash
-63.07M-119.84%
Free cash flow
-15.60M-110.51%
StockDE listed securityCH headquartered
Previous close
€38.20
Day range
€37.40 - €38.80
Year range
€29.20 - €38.80
Market cap
3.59B USD
Avg Volume
331.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Founded
2013
Employees
393
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
Search
Clear search
Close search
Main menu
Google apps